Global PD-1 and PD-L1 Inhibitors Market Size, Share, Trends and Forecast 2022-2030

Description

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.
Industry Insights

Due to the COVID-19 pandemic, the global PD-1 and PD-L1 Inhibitors market size is estimated to be worth US$ 39550 million in 2021 and is forecast to a readjusted size of US$ 145420 million by 2028 with a CAGR of 20.2% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe PD-1 and PD-L1 Inhibitors market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe PD-1 and PD-L1 Inhibitors landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

North America is the largest consumption place, with a consumption market share nearly 60.40% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 20.66%.Market competition is intense. Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical etc. are the leaders of the industry.

This report focuses on PD-1 and PD-L1 Inhibitors volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall PD-1 and PD-L1 Inhibitors market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Japan and China, etc.

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Post-covid-19 Outlook

The readers in the section will understand how the PD-1 and PD-L1 Inhibitors market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Segmental Outlook

Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).

Segment by Type

PD-1 Inhibitors

PD-L1 Inhibitors

Segment by Application

Solid Tumors

Blood-related Tumors

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Competitive Scenario

In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Merck

Bristol-Myers Squibb

Roche

AstraZeneca

Ono Pharmaceutical

Regeneron

Innovent

Hengrui Medicine

Junshi Biosciences

Merck KGaA

TABLE OF CONTENT

1 PD-1 and PD-L1 Inhibitors Market Overview
1.1 Product Overview and Scope of PD-1 and PD-L1 Inhibitors

1.2 PD-1 and PD-L1 Inhibitors Segment by Type

1.2.1 Global PD-1 and PD-L1 Inhibitors Sales Growth Rate Comparison by Type (2022-2028)

1.2.2 PD-1 Inhibitors

1.2.3 PD-L1 Inhibitors

1.3 PD-1 and PD-L1 Inhibitors Segment by Application

1.3.1 Global PD-1 and PD-L1 Inhibitors Sales Comparison by Application: (2022-2028)

1.3.2 Solid Tumors

1.3.3 Blood-related Tumors

1.4 Global PD-1 and PD-L1 Inhibitors Market Size Estimates and Forecasts

1.4.1 Global PD-1 and PD-L1 Inhibitors Revenue 2017-2028

1.4.2 Global PD-1 and PD-L1 Inhibitors Sales 2017-2028

1.4.3 PD-1 and PD-L1 Inhibitors Market Size by Region: 2017 Versus 2021 Versus 2028

2 PD-1 and PD-L1 Inhibitors Market Competition by Manufacturers

2.1 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Manufacturers (2017-2022)

2.2 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Manufacturers (2017-2022)

2.3 Global PD-1 and PD-L1 Inhibitors Average Price by Manufacturers (2017-2022)

2.4 Manufacturers PD-1 and PD-L1 Inhibitors Manufacturing Sites, Area Served, Product Type

2.5 PD-1 and PD-L1 Inhibitors Market Competitive Situation and Trends

2.5.1 PD-1 and PD-L1 Inhibitors Market Concentration Rate

2.5.2 The Global Top 5 and Top 10 Largest PD-1 and PD-L1 Inhibitors Players Market Share by Revenue

2.5.3 Global PD-1 and PD-L1 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 PD-1 and PD-L1 Inhibitors Retrospective Market Scenario by Region

3.1 Global PD-1 and PD-L1 Inhibitors Retrospective Market Scenario in Sales by Region: 2017-2022

3.2 Global PD-1 and PD-L1 Inhibitors Retrospective Market Scenario in Revenue by Region: 2017-2022

3.3 North America PD-1 and PD-L1 Inhibitors Market Facts & Figures by Country

3.3.1 North America PD-1 and PD-L1 Inhibitors Sales by Country

3.3.2 North America PD-1 and PD-L1 Inhibitors Revenue by Country

3.3.3 U.S.

3.3.4 Canada

3.4 Europe PD-1 and PD-L1 Inhibitors Market Facts & Figures by Country

3.4.1 Europe PD-1 and PD-L1 Inhibitors Sales by Country

3.4.2 Europe PD-1 and PD-L1 Inhibitors Revenue by Country

3.4.3 Germany

3.4.4 France

3.4.5 U.K.

3.4.6 Italy

3.4.7 Russia

3.5 Asia Pacific PD-1 and PD-L1 Inhibitors Market Facts & Figures by Region

3.5.1 Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Region

3.5.2 Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Region

3.5.3 China

3.5.4 Japan

3.5.5 South Korea

3.5.6 India

3.5.7 Australia

3.5.8 Taiwan

3.5.9 Indonesia

3.5.10 Thailand

3.5.11 Malaysia

3.5.12 Philippines

3.5.13 Vietnam

3.6 Latin America PD-1 and PD-L1 Inhibitors Market Facts & Figures by Country

3.6.1 Latin America PD-1 and PD-L1 Inhibitors Sales by Country

3.6.2 Latin America PD-1 and PD-L1 Inhibitors Revenue by Country

3.6.3 Mexico

3.6.4 Brazil

3.6.5 Argentina

3.7 Middle East and Africa PD-1 and PD-L1 Inhibitors Market Facts & Figures by Country

3.7.1 Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Country

3.7.2 Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Country

3.7.3 Turkey

3.7.4 Saudi Arabia

3.7.5 UAE

4 Global PD-1 and PD-L1 Inhibitors Historic Market Analysis by Type

4.1 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2017-2022)

4.2 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2017-2022)

4.3 Global PD-1 and PD-L1 Inhibitors Price by Type (2017-2022)

5 Global PD-1 and PD-L1 Inhibitors Historic Market Analysis by Application

5.1 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2017-2022)

5.2 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2017-2022)

5.3 Global PD-1 and PD-L1 Inhibitors Price by Application (2017-2022)

6 Key Companies Profiled

6.1 Merck

6.1.1 Merck Corporation Information

6.1.2 Merck Description and Business Overview

6.1.3 Merck PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.1.4 Merck PD-1 and PD-L1 Inhibitors Product Portfolio

6.1.5 Merck Recent Developments/Updates

6.2 Bristol-Myers Squibb

6.2.1 Bristol-Myers Squibb Corporation Information

6.2.2 Bristol-Myers Squibb Description and Business Overview

6.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Portfolio

6.2.5 Bristol-Myers Squibb Recent Developments/Updates

6.3 Roche

6.3.1 Roche Corporation Information

6.3.2 Roche Description and Business Overview

6.3.3 Roche PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.3.4 Roche PD-1 and PD-L1 Inhibitors Product Portfolio

6.3.5 Roche Recent Developments/Updates

6.4 AstraZeneca

6.4.1 AstraZeneca Corporation Information

6.4.2 AstraZeneca Description and Business Overview

6.4.3 AstraZeneca PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.4.4 AstraZeneca PD-1 and PD-L1 Inhibitors Product Portfolio

6.4.5 AstraZeneca Recent Developments/Updates

6.5 Ono Pharmaceutical

6.5.1 Ono Pharmaceutical Corporation Information

6.5.2 Ono Pharmaceutical Description and Business Overview

6.5.3 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.5.4 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Portfolio

6.5.5 Ono Pharmaceutical Recent Developments/Updates

6.6 Regeneron

6.6.1 Regeneron Corporation Information

6.6.2 Regeneron Description and Business Overview

6.6.3 Regeneron PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.6.4 Regeneron PD-1 and PD-L1 Inhibitors Product Portfolio

6.6.5 Regeneron Recent Developments/Updates

6.7 Innovent

6.6.1 Innovent Corporation Information

6.6.2 Innovent Description and Business Overview

6.6.3 Innovent PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Innovent PD-1 and PD-L1 Inhibitors Product Portfolio

6.7.5 Innovent Recent Developments/Updates

6.8 Hengrui Medicine

6.8.1 Hengrui Medicine Corporation Information

6.8.2 Hengrui Medicine Description and Business Overview

6.8.3 Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.8.4 Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Portfolio

6.8.5 Hengrui Medicine Recent Developments/Updates

6.9 Junshi Biosciences

6.9.1 Junshi Biosciences Corporation Information

6.9.2 Junshi Biosciences Description and Business Overview

6.9.3 Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.9.4 Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Portfolio

6.9.5 Junshi Biosciences Recent Developments/Updates

6.10 Merck KGaA

6.10.1 Merck KGaA Corporation Information

6.10.2 Merck KGaA Description and Business Overview

6.10.3 Merck KGaA PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2017-2022)

6.10.4 Merck KGaA PD-1 and PD-L1 Inhibitors Product Portfolio

6.10.5 Merck KGaA Recent Developments/Updates

7 PD-1 and PD-L1 Inhibitors Manufacturing Cost Analysis

7.1 PD-1 and PD-L1 Inhibitors Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Key Suppliers of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.3 Manufacturing Process Analysis of PD-1 and PD-L1 Inhibitors

7.4 PD-1 and PD-L1 Inhibitors Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

8.1 Marketing Channel

8.2 PD-1 and PD-L1 Inhibitors Distributors List

8.3 PD-1 and PD-L1 Inhibitors Customers

9 PD-1 and PD-L1 Inhibitors Market Dynamics

9.1 PD-1 and PD-L1 Inhibitors Industry Trends

9.2 PD-1 and PD-L1 Inhibitors Market Drivers

9.3 PD-1 and PD-L1 Inhibitors Market Challenges

9.4 PD-1 and PD-L1 Inhibitors Market Restraints

10 Global Market Forecast

10.1 PD-1 and PD-L1 Inhibitors Market Estimates and Projections by Type

10.1.1 Global Forecasted Sales of PD-1 and PD-L1 Inhibitors by Type (2023-2028)

10.1.2 Global Forecasted Revenue of PD-1 and PD-L1 Inhibitors by Type (2023-2028)

10.2 PD-1 and PD-L1 Inhibitors Market Estimates and Projections by Application

10.2.1 Global Forecasted Sales of PD-1 and PD-L1 Inhibitors by Application (2023-2028)

10.2.2 Global Forecasted Revenue of PD-1 and PD-L1 Inhibitors by Application (2023-2028)

10.3 PD-1 and PD-L1 Inhibitors Market Estimates and Projections by Region

10.3.1 Global Forecasted Sales of PD-1 and PD-L1 Inhibitors by Region (2023-2028)

10.3.2 Global Forecasted Revenue of PD-1 and PD-L1 Inhibitors by Region (2023-2028)

11 Research Finding and Conclusion

12 Methodology and Data Source

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Author List

12.4 Disclaimer

Choose License Type

Checkout Inquiry Sample